Jinming Zhou | Medicinal Chemistry | Best Researcher Award

Posted on by sciencefather

Dr. Jinming Zhou | Medicinal Chemistry| Best Researcher Award

Research and Grant Success:

  • Dr. Zhou’s research has been consistently supported by prestigious National Natural Science Foundation (NCSF) grants, with four approvals to date. This grant success not only reflects the high quality and impact of his research but also indicates his capacity to conduct rigorous and relevant studies that address critical health challenges.
Dr. Jinming Zhou, Zhejiang Normal University , China

Profile

Scopus

OrcID

🌱EARLY ACADEMIC PURSUITS

  • Dr. Zhou’s academic journey began at Beijing Normal University, where he earned his Bachelor of Science (B.S.) in 2000 and Master of Science (M.S.) in 2003. His passion for rational drug design led him to pursue a Ph.D. at the Shanghai Institute of Organic Chemistry, where he specialized in this field, establishing a strong foundation in medicinal chemistry. Postdoctoral training followed at McGill University in Canada, where he continued advancing in rational drug design and gained international research exposure.

💼 PROFESSIONAL ENDEAVORS

  • In 2010, Dr. Zhou joined the Institute of Medicinal Biotechnology at the Chinese Academy of Medical Science as an Associate Professor. Demonstrating outstanding contributions in drug research, he achieved full professorship in 2017. His career took a new turn in 2018 when he accepted a professorship at Zhejiang Normal University, where he also became the Director of the Drug Development and Innovation Center. Dr. Zhou’s leadership at this center has been pivotal in establishing innovative practices and groundbreaking projects.

🔬CONTRIBUTIONS AND RESEARCH FOCUS 

  • Dr. Zhou’s research team is at the forefront of developing anti-viral and anti-cancer drugs. His group combines rational drug design and applied medicinal research to create effective therapeutic solutions. His work has a special emphasis on translational medicine, aiming to bridge scientific research and clinical applications. He has secured four prestigious National Natural Science Foundation (NCSF) grants, supporting his work in advancing therapeutic drug development.

📚ACADEMIC CITES 

  • With over a hundred publications, Dr. Zhou has significantly impacted medicinal chemistry, particularly in antiviral and anticancer drug design. His research has become a widely cited reference in related studies, underscoring his scientific contributions’ value and relevance.

🌍IMPACT AND INFLUENCE

  • Dr. Zhou’s influence in the medicinal chemistry field is highlighted by his 100+ publications in high-impact journals, showcasing the scientific community’s recognition of his expertise. His achievements were honored in 2012 with the prestigious “Xiehe Star” award, recognizing his exceptional contributions to the field of drug design.

🌟LEGACY AND FUTURE AND CONTRIBUTIONS

  • As Dr. Zhou continues his work at the Drug Development and Innovation Center, he is shaping a new generation of researchers focused on tackling global health challenges. His legacy is built not only on his published works but also on his mentorship and role in expanding the field of drug innovation. His ongoing research promises to further the understanding of rational drug design and its applications in combating complex diseases.

📄Publications

  • “Inducing or enhancing protein-protein interaction to develop drugs: Molecular glues with various biological activity”
    Authors: Zhang, R., Zheng, Y., Xiang, F., Zhou, J.
    Journal: European Journal of Medicinal Chemistry, 2024, 277, 116756
  • “METTL3 inhibitor suppresses the progression of prostate cancer via IGFBP3/AKT pathway and synergizes with PARP inhibitor”
    Authors: Chen, X., Wang, M., Wang, H., Zhou, J., Wu, M.
    Journal: Biomedicine and Pharmacotherapy, 2024, 179, 117366
  • “Autophagy mediated targeting degradation, a promising strategy in drug development”
    Authors: Zhang, J., Pan, X., Ji, W., Zhou, J.
    Journal: Bioorganic Chemistry, 2024, 149, 107466
  • “A novel hydrophobic tag leads to the efficient degradation of programmed death-ligand 1”
    Authors: Gao, J., Xie, Y., Zhang, J., Cen, S., Zhou, J.
    Journal: RSC Medicinal Chemistry, 2024, 15(9), pp. 3038–3047
  • “Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer”
    Authors: Li, C., Han, X., Yan, Q., Wu, M., Zhou, J.
    Journal: Journal of Medicinal Chemistry, 2024, 67(5), pp. 3419–3436

Xuan Zhang | Pharmacology | Best Researcher Award

Posted on by sciencefather

Prof Dr . Xuan Zhang | Pharmacology | Best Researcher Award

Patent Contributions:
  • Dr. Zhang has contributed to various patent filings, showcasing his practical contributions to drug development and medical devices. His patents, especially in areas like anti-pulmonary fibrosis drugs and innovative drug transport simulation devices, highlight his forward-thinking approach and leadership in pharmaceutical innovation
  Prof Dr. Xuan Zhang , Kunming Medical University , China

Profile

Scopus

OrcID

🎓Early Academic Pursuits

  • Xuan Zhang’s academic journey began with a Bachelor of Medicine in Clinical Medicine from Changzhi Medical University in July 2003. he further honed his expertise by obtaining a Master of Medicine in Pharmacology from Kunming Medical University in July 2006. His pursuit of knowledge continued with a Ph.D. in Cell Biology from the University of Chinese Academy of Sciences in January 2013. These academic milestones provided her with a solid foundation in pharmacology and cell biology, setting the stage for his future contributions to anti-inflammatory and immunopharmacological research.

💼Professional Endeavors

  • Dr. Xuan Zhang has had an impressive professional trajectory. he began his research career as a Research Assistant at the Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University from August 2009 to July 2013. His commitment and excellence led to her appointment as an Associate Professor at the same institution, where he worked from August 2013 to September 2021. During this time, he expanded her academic horizons as a Visiting Scholar at the University of Nebraska Medical Center from January to July 2018. In October 2021, she achieved the rank of Professor at the School of Pharmaceutical Sciences & Yunnan Key Laboratory of Pharmacology for Natural Products.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS

  • Dr. Xuan Zhang’s research primarily focuses on anti-inflammatory and immunopharmacology and respiratory pharmacology. His work centers on understanding the pathogenesis and drug development for organ inflammation and fibrosis, with a special emphasis on lung-related conditions. Throughout her career, he has contributed significantly to uncovering molecular mechanisms, particularly in the context of pulmonary fibrosis and acute lung injury. His research projects, funded by prestigious organizations such as the National Natural Science Foundation of China and the Yunnan Provincial Department of Science and Technology, showcase her expertise and her leadership in exploring pharmacological interventions.

🏅ACADEMIC CITES 

  • Dr. Zhang’s academic contributions are extensively cited in the fields of pharmacology and respiratory medicine. His research has garnered attention from scholars worldwide, establishing his as a leading figure in the study of organ fibrosis. His work is continuously referenced in top journals, furthering the understanding of cell signaling pathways and inflammation management.

🏆IMPACT AND INFLUENCE

  • Dr. Zhang has completed a number of important research projects that have advanced the understanding of acute lung injury and pulmonary fibrosis, notably involving compounds like Palmatin and Gentiopicroside. These projects have yielded practical insights into therapeutic approaches, especially concerning key signaling pathways such as MAPK and NF-κB in lung injury. Moreover, his collaborative work with industry has had tangible impacts on pharmaceutical development, particularly in his consultancy projects evaluating vaccine effectiveness and the safety of novel compounds.

🧬PROFESSIONAL MEMBERSHIPS

  • Dr. Zhang is an active member of several prominent organizations, including the Chinese Pharmacological Society and the Yunnan Pharmacological Society. His roles as Deputy Secretary-General and Standing Member of these societies underline her leadership and dedication to advancing pharmacology both in China and internationally.

🔮LEGACY AND FUTURE CONTRIBUTIONS

  • Dr. Zhang’s patents, particularly in the domain of anti-pulmonary fibrosis drugs and innovative drug transport simulation devices, signify her commitment to translating research into practical applications. His continued involvement in groundbreaking research on iridoid glycosides and Geniposide is expected to yield new therapies for pulmonary fibrosis. His current projects, funded by the National Natural Science Foundation and Kunming Medical University, promise to cement his legacy as a pioneer in the field. he is also recognized as a young and middle-aged academic and technical leader in Yunnan Province, ensuring that his influence will extend to future generations of researchers.

📰PUBLICATIONS

  •  Geniposide Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice by Inhibiting TGF-β/Smad and p38MAPK Signaling Pathways
    Authors: Yin, J.-B., Wang, Y.-X., Fan, S.-S., Zou, C., Zhang, X.
    Journal: PLoS ONE, 2024, 19(9), e0309833.
  • Mechanism of Xiyanping Injection in Treatment of Acute Lung Injury Using Network Pharmacology and Molecular Docking Analysis
    Authors: Nie, S.-Y., Fan, S.-S., Zhu, Y.-S., Wang, Y.-X., Zhang, X.
    Journal: Chinese Pharmacological Bulletin, 2024, 40(6), pp. 1165–1171.
  • Adult Pancreatoblastoma with Atypical Histological Morphology Combined with Familial Adenomatous Polyposis: A Rare Case Report
    Authors: Wang, Y.-X., Fan, S.-S., Peng, X.-R., Zhu, Y.-S., Zhang, X.
    Journal: Frontiers in Oncology, 2024, 14, 1346964.
  • Case Report: Clinicopathological Analysis of Minute Pulmonary Meningothelial-Like Nodules: Report of 7 Cases
    Authors: Wang, Y.-X., Lei, Z., Yang, M., Zhang, X., Pan, G.-Q.
    Journal: Frontiers in Oncology, 2022, 12, 942517.
  •  New 4,5-seco-20(10→5)-abeo-Abietane Diterpenoids with Anti-Inflammatory Activity from Isodon lophanthoides var. graciliflorus (Benth.) H.Hara
    Authors: Chen, W.-F., Wong, L.-L., Zhang, X., Tang, L.-P., Li, X.
    Journal: Chemistry and Biodiversity, 2019, 16(6), e1900206.